gadoteridol

gad·o·ter·i·dol

(gad'ō-ter'i-dol),
A nonionic macrocyclic analogue of gadolinium DOTA; used as a paramagnetic contrast medium in magnetic resonance imaging.
References in periodicals archive ?
Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol.
Kumar, "Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats," Investigative Radiology, vol.
Closely related diagnostic agents are gadobenate dimeglumine (MultiHance), gadodiamide (Omniscan), gadofosveset (Ablavar), gadopentetate dimeglumine (Magnevist), gadoteridol (Prohance), and gadoversetamide (OptiMARK).
2 1) Gadoteridol 2) Gadobenate dimeglumine 3) Iomeprol 400 mg / ml 4) Iomeprol 350mg/ml Package No.
Various MR contrast agents are available on the market--gadodiamide (Omniscan), gadopentetate (Magnascan), gadoteridol (Prohance), etc.
There are five gadolinium-based contrast agents approved for use in the United States: gadodiarnide, gadoversetamide (OptiMARK), gadopentetate dimeglumine (Magnevist), gadoteridol (ProHance), and gadobenate dimeglumine (Multihance).
These agents are gadodimide (Omniscan[R]), gadoversetamide (OptiMARK[R]), gadopentetate dimeglumine (Magnevist[R]), gadoteridol (ProHance[R]), and gadobenate dimeglumine (MultiHance[R]).
Currently, there are four gadolinium-based contrast agents available commercially in the U5: gadodiamide (Omniscan; Amersham Health), gadopentetate dimeglumine (Magnevist; Schering), gadoversetamide (OptiMARK; Mallinckrodt Medical), and gadoteridol (Prohance; Bracco).
The stability constant of gadoteridol, which is another chelate that does not affect the OCP method, is 25.
Also, Group II gadolinium-based agents, such as gadoteridol and gadobenate dimeglumine, should be used rather than Group I agents like gadodiamide and gadopentatate dimeglumine, which are associated with the greatest number of NSF cases.
13) A mild case of NSF has been documented following multiple exposures to gadoteridol (ProHance, Bracco Diagnostics, Inc.
Wayne, NJ) Gadobenate dimeglumine (Gd-BOPTA) (MultiHance, Bracco Diagnostics, Princeton, NJ) Nonionic and linear Gadodiamide (Gd-DTPA-BMA) (Omniscan, GE Healthcare, Princeton, NJ) Ionic and cyclic Gadoterate meglumine (Gd-DOTA) (Dotarem/Artirem, Guerbet SA, Roissy, France) Nonionic and cyclic Gadoteridol (Gd-HP-DO3A) (ProHance, Bracco Diagnostics) Gadobutrol (Gd-DO3A-butriol) (Gadovist, Berlex Laboratories) Table 2.